'Merck Keeps Kinase Inhibitor Options Open As It Partners With Exelixis To Test Zanzalintinib Alongside Welireg In Renal Cancer; Collaboration Raises Questions About Merck's Ongoing Renal Trials With Lenvima, Litespark-011 Trial Completion Is Delayed...
'Merck Keeps Kinase Inhibitor Options Open As It Partners With Exelixis To Test Zanzalintinib Alongside Welireg In Renal Cancer; Collaboration Raises Questions About Merck's Ongoing Renal Trials With Lenvima, Litespark-011 Trial Completion Is Delayed...
默沙東與伊克力西斯合作，在腎癌中測試Zanzalintinib與Welireg聯用，保持激酶抑制劑期權開放；合作引發關於默沙東正在進行的與樂普瑞、Litespark-011試驗完成日期延遲的疑問...
'Merck Keeps Kinase Inhibitor Options Open As It Partners With Exelixis To Test Zanzalintinib Alongside Welireg In Renal Cancer; Collaboration Raises Questions About Merck's Ongoing Renal Trials With Lenvima, Litespark-011 Trial Completion Is Delayed To 2026; Companies To Co-Fund Phase 1/2 Trial With Merck Sponsoring Two Phase 3 Studies; Merck To Supply Keytruda For Exelixis-Sponsored Head And Neck Cancer Trial' - Oncology Pipeline
默沙東保持激酶抑制劑期權開放，與伊克力西斯合作在腎癌中測試Zanzalintinib和Welireg聯合使用；合作引起了關於默沙東正在進行中的利普羅的腎癌試驗和Litespark-011試驗完成推遲至2026年的疑問；兩家公司將共同資助1/2期試驗，默沙東贊助兩項第三階段研究；默沙東將爲伊克力西斯贊助的頭頸癌試驗提供Keytruda。- 腫瘤學管道
資訊熱榜
更新時間